Entourage Health Corp. (ENTG.V)
CAD 0.01
(0.0%)
CAD 0.01
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -21.37 Million CAD | 62.4% |
| 2022 | -52.24 Million CAD | -45.54% |
| 2021 | -35.89 Million CAD | 24.29% |
| 2020 | -47.41 Million CAD | -637.3% |
| 2019 | -6.43 Million CAD | 31.4% |
| 2018 | -9.37 Million CAD | -31.12% |
| 2017 | -7.14 Million CAD | -7166.05% |
| 2016 | -98.4 Thousand CAD | -200.2% |
| 2015 | -32.77 Thousand CAD | 74.94% |
| 2014 | -130.82 Thousand CAD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -3.52 Million CAD | -1026.03% |
| 2024 Q1 | 380.6 Thousand CAD | 104.33% |
| 2023 FY | -19.64 Million CAD | 62.4% |
| 2023 Q1 | -9.54 Million CAD | 55.47% |
| 2023 Q4 | -8.78 Million CAD | -157.82% |
| 2023 Q2 | -2.5 Million CAD | 73.8% |
| 2023 Q3 | -3.4 Million CAD | -36.21% |
| 2022 Q2 | -17.44 Million CAD | -99.08% |
| 2022 Q3 | -17.5 Million CAD | -0.36% |
| 2022 FY | -52.24 Million CAD | -45.54% |
| 2022 Q1 | -8.76 Million CAD | 4.87% |
| 2022 Q4 | -21.43 Million CAD | -22.42% |
| 2021 FY | -35.89 Million CAD | 24.29% |
| 2021 Q3 | -14.63 Million CAD | -94.52% |
| 2021 Q4 | -9.21 Million CAD | 37.04% |
| 2021 Q2 | -7.52 Million CAD | -66.17% |
| 2021 Q1 | -4.52 Million CAD | 89.11% |
| 2020 Q3 | 9.42 Million CAD | 222.95% |
| 2020 Q4 | -41.55 Million CAD | -540.88% |
| 2020 Q1 | -7.61 Million CAD | -83.19% |
| 2020 Q2 | -7.66 Million CAD | -0.64% |
| 2020 FY | -47.41 Million CAD | -637.3% |
| 2019 Q3 | -13.02 Million CAD | -198.98% |
| 2019 Q1 | -2.4 Million CAD | 68.86% |
| 2019 Q2 | 13.16 Million CAD | 646.98% |
| 2019 Q4 | -4.15 Million CAD | 68.08% |
| 2019 FY | -6.43 Million CAD | 31.4% |
| 2018 Q2 | -1.18 Million CAD | -47.95% |
| 2018 FY | -9.37 Million CAD | -31.12% |
| 2018 Q4 | -7.72 Million CAD | -1730.38% |
| 2018 Q3 | 473.93 Thousand CAD | 140.07% |
| 2018 Q1 | -799.38 Thousand CAD | 56.77% |
| 2017 Q2 | -3.14 Million CAD | -716.08% |
| 2017 FY | -7.14 Million CAD | -7166.05% |
| 2017 Q4 | -1.84 Million CAD | -226.41% |
| 2017 Q1 | -385.37 Thousand CAD | -569.28% |
| 2017 Q3 | -566.56 Thousand CAD | 81.99% |
| 2016 Q1 | -6081.00 CAD | 72.98% |
| 2016 Q4 | -57.58 Thousand CAD | -444.66% |
| 2016 Q3 | -10.57 Thousand CAD | 56.26% |
| 2016 Q2 | -24.16 Thousand CAD | -297.43% |
| 2016 FY | -98.4 Thousand CAD | -200.2% |
| 2015 Q3 | -616.00 CAD | 81.9% |
| 2015 FY | -32.77 Thousand CAD | 74.94% |
| 2015 Q2 | -3403.00 CAD | 45.56% |
| 2015 Q1 | -6251.00 CAD | 94.24% |
| 2015 Q4 | -22.5 Thousand CAD | -3554.06% |
| 2014 Q3 | -22.24 Thousand CAD | 0.0% |
| 2014 FY | -130.82 Thousand CAD | 0.0% |
| 2014 Q4 | -108.57 Thousand CAD | -388.09% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Aequus Pharmaceuticals Inc. | -2.82 Million CAD | -658.008% |
| CanadaBis Capital Inc. | 4.67 Million CAD | 557.099% |
| Decibel Cannabis Company Inc. | 1.41 Million CAD | 1614.022% |
| Delivra Health Brands Inc. | -710 Thousand CAD | -2910.985% |
| Lifeist Wellness Inc. | -12.24 Million CAD | -74.514% |
| Cannara Biotech Inc. | 11.88 Million CAD | 279.831% |
| Medicure Inc. | -854 Thousand CAD | -2403.278% |
| PharmaCielo Ltd. | -9.7 Million CAD | -120.37% |
| Rubicon Organics Inc. | -1.08 Million CAD | -1873.15% |
| BioSyent Inc. | 7.47 Million CAD | 386.141% |
| Voyageur Pharmaceuticals Ltd. | -1.22 Million CAD | -1650.928% |